Dr. Eric Jonasch

It is important to expand clinical trial access for patients with kidney cancer in order to ensure a representative study population.

The HIF-2a Inhibitor induced clinical responses among patients with von Hippel-Lindau disease–associated kidney cancer, according to results presented at the 2020 ASCO Virtual Scientific Program.